Tony Mok - Astrazeneca PLC Non-Executive Independent Director

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>AP</div>
AZN -- USA Stock  

Report: 30th of July 2020  

  Director
Prof. Tony S. K. Mok is NonExecutive Independent Director of the Company. Professor Tony S K Mok was trained at the University of Alberta, Canada and subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital in Toronto. After working as a community oncologist in Toronto, Canada for seven years, he returned to Hong Kong in 1996 to pursue an academic career. Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of the Department of Clinical Oncology at the Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the principal investigator and first author on the landmark Iressa PanAsia Study, which was the first trial that confirmed the application of precision medicine for advanced lung cancer. He has led and coled multiple other international Phase III trials, addressing various aspects of the management of advanced lung cancer. His work also includes clinical research on oncogene driven lung cancer and immunotherapy and he contributes to the development of clinical research infrastructure in China and Asia. He cofounded the Lung Cancer Research Group, the Chinese Thoracic Oncology Research Group and the Asia Thoracic Oncology Research Group. Professor Mok has contributed to over 250 articles in international peerreviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. He is the pastPresident and current Treasurer of the International Association for the Study of Lung Cancer and serves on the Board of Directors of the American Society of Clinical Oncology .
  Director Since 2019      
(44) 1223 352 858  www.astrazeneca.com

Astrazeneca PLC Management Efficiency

Astrazeneca PLC has Return on Asset of 3.6 % which means that on every $100 spent on asset it made $3.6 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.66 %, implying that it generated $11.66 on every 100 dollars invested. Astrazeneca PLC management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Return on Investment is projected to rise to 9.64 this year. Return on Average Assets is projected to rise to 0.0205 this yearAstrazeneca PLC Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at about 0.41. Return on Average Assets is projected to rise to 0.0205 this year, although the value of Tax Assets will most likely fall to about 2.6 B. Astrazeneca PLC Total Liabilities is quite stable at the moment as compared to the past year. The company's current value of Total Liabilities is estimated at about 46.98 Billion. Current Liabilities is projected to rise to about 18.9 B this year, although the value of Liabilities Non Current will most likely fall to about 28.1 B.
The company has 20.98 B in debt with debt to equity (D/E) ratio of 1.72, which is OK given its current industry classification. Astrazeneca PLC has a current ratio of 0.74, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Eugene WashingtonJohnson Johnson
2012
Inigo MardonesGrifols S A
2017
Jackson TaiEli Lilly And
2013
Kathy WardenMerck Company
2020
Karen HornEli Lilly And
2012
Jennifer DoudnaJohnson Johnson
2018
Richard WhitleyGilead Sciences
2008
Stacey CartwrightGlaxoSmithKline PLC
2011
David HooverEli Lilly And
2009
Mark WeinbergerJohnson Johnson
2019
Harish ManwaniGilead Sciences
2018
Wendell WeeksMerck Company
2004
Laurie GlimcherGlaxoSmithKline PLC
2017
Gerald StorchBristol Myers Squibb
2012
Pamela CraigMerck Company
2015
William HarrisonMerck Company
2009
Paul RothmanMerck Company
2015
Luis BobadillaGrifols S A
2011
Jacqueline BartonGilead Sciences
2018
Mateo HumbertGrifols S A
2014
Julian GangolliGW Pharmaceuticals Plc
2015

Company Summary

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 70600 people.Astrazeneca PLC (AZN) is traded on BATS Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom and employs 70,600 people. Astrazeneca PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

Astrazeneca PLC Leadership Team

Marc Dunoyer, Chief Financial Officer, Executive Director
Sherilyn McCoy, Non-Executive Independent Director
Genevieve Berger, Non-Executive Independent Director
Luke Miels, Executive Vice-President GPPS
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development
Paul Hudson, Executive Vice President North America
Nazneen Rahman, Non-Executive Independent Director
Jose Baselga, Executive Vice President - Research & Development Oncology
JeanPhilippe Courtois, Non-Executive Independent Director
Thomas Larsen, IR Contact Officer
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer
Tony Mok, Non-Executive Independent Director
Mark Mallon, Executive Vice President International
Fiona Cicconi, Executive Vice President - Human Resources
Deborah DiSanzo, Non-Executive Independent Director
Shriti Vadera, Non-Executive Independent Director
Leif Johansson, Non-Executive Independent Chairman of the Board
Leon Wang, Executive Vice President - International and China President
Ann Cairns, Non-Executive Director
Adrian Kemp, Company Secretary
Cornelia Bargmann, Non-Executive Director
Tim JacksonSmith, Non-Executive Director
Michel Demare, Non-Executive Independent Director
Graham Chipchase, Senior Non-Executive Independent Director
David Smith, Executive VP of Operations and Information Services
Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee
Pam Cheng, Executive Vice-President of Operations and Information Technology
Baroness Vadera, Non-Executive Independent Director
Philip Broadley, Non-Executive Independent Director
Narayan Seshadri, Independent Director
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business
David Fredrickson, Executive Vice-President Global Head Oncology Business Unit
Bahija Jallal, Executive Vice President MedImmune
Rudolph Markham, Non-Executive Independent Director
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals
Weiying Wang, Non-Executive Director
Bruce Burlington, Non-Executive Independent Director
Marcus Wallenberg, Non-Executive Director
Iskra Reic, Executive Vice President - Europe and Canada

Stock Performance Indicators

Did you try this?

Run Equity Analysis Now

   

Equity Analysis

Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
All  Next Launch Module

Astrazeneca PLC Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Astrazeneca PLC and Gilead Sciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page